Dr. Karen Gelmon is Professor of Medicine, Co Chair NCIC Clinical Trials Group Breast Site Committee, Clinical Head of the Investigational Drug Programme, and Medical Oncologist, Department of Medical Oncology, University of British Columbia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Overexpression of HER2 protein in breast tumors is associated with an aggressive tumor phenotype and poor prognosis. In this “When the Smoke Clears” interview, Karen Gelmon, MD, discusses the...